TARRYTOWN, N.Y., June 29, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
today announced that it will report its second quarter 2023 financial and operating results on
Thursday, August 3, 2023, before the U.S. financial markets open. The Company will host a conference
call and simultaneous webcast at 8:30 AM Eastern Time that day. About Regeneron  Regeneron (NASDAQ:
REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming
medicines for people with serious diseases. Founded and led for 35 years by physician-scientists,
our unique ability to repeatedly and consistently translate science into medicine has led to nine
FDA-approved treatments and numerous product candidates in development, almost all of which were
homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye
diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain,
hematologic conditions, infectious diseases and rare diseases. Regeneron is accelerating and
improving the traditional drug development process through our proprietary VelociSuite
technologies, such as VelocImmune , which uses unique genetically humanized mice to produce
optimized fully human antibodies and bispecific antibodies, and through ambitious research
initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics
sequencing efforts in the world.